ABT‑737 and pictilisib synergistically enhance pitavastatin‑induced apoptosis in ovarian cancer cells

De Wolf,Elizabeth; De Wolf,Christopher; Richardson,Alan

doi:10.3892/ol.2017.7516

ABT‑737 and pictilisib synergistically enhance pitavastatin‑induced apoptosis in ovarian cancer cells

Authors:
- Elizabeth De Wolf
- Christopher De Wolf
- Alan Richardson
View Affiliations

Affiliations: Institute for Science and Technology in Medicine, Guy Hilton Research Centre, Stoke‑on‑Trent ST4 7QB, UK
Published online on: December 5, 2017 https://doi.org/10.3892/ol.2017.7516
Pages: 1979-1984

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There is considerable interest in redeploying drugs for use in combination with other oncology therapeutics. The single‑agent activity of statins in ovarian cancer has been widely reported, however the drug concentration required to cause cell death is considerably higher than that achieved in patients receiving statin treatment for hypercholesterolemia. Unfortunately, statins can cause myopathy when administered in high doses. One solution to this is to identify drugs that could be used in combination with statins to reduce the dose required and those that may potentially reduce the incidence of adverse side effects. When the BH3 mimetic ABT‑737, or the phosphatidylinositol 3‑kinase inhibitor pictilisib, were combined with pitavastatin in cell growth assays using Ovcar‑3 and Igrov‑1 cells, the drug combinations were more effective than pitavastatin alone. In support of this, ABT‑737 or pictilisib markedly increased cell death induced by pitavastatin in several ovarian cancer cell lines. The drugs were also synergistic in apoptosis assays. These observations suggested that either BH3 mimetics or pictilisib in combination with pitavastatin could be used in a subset of ovarian tumours, particularly those sensitive to BH3 mimetics, and phosphatase and tensin homolog inhibition, in the treatment of ovarian cancer.

View Figures

View References

1	Robinson E, Nandi M, Wilkinson LL, Arrowsmith DM, Curtis AD and Richardson A: Preclinical evaluation of statins as a treatment for ovarian cancer. Gynecol Oncol. 129:417–424. 2013. View Article : Google Scholar : PubMed/NCBI
2	de Wolf E, Abdullah MI, Jones S, Menezes K, Moss DM, Drijfhout FP, Hart SR, Hoskins C, Stronach EA and Richardson A: Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer. Sci Rep. 7:54102017. View Article : Google Scholar : PubMed/NCBI
3	Mukhtar RY, Reid J and Reckless JP: Pitavastatin. Int J Clin Pract. 59:239–252. 2005. View Article : Google Scholar : PubMed/NCBI
4	Ando H, Tsuruoka S, Yanagihara H, Sugimoto K, Miyata M, Yamazoe Y, Takamura T, Kaneko S and Fujimura A: Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol. 60:494–497. 2005. View Article : Google Scholar : PubMed/NCBI
5	Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, Lim KS, Moon KH, Shin SG and Jang IJ: Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther. 78:342–350. 2005. View Article : Google Scholar : PubMed/NCBI
6	Hui CK, Cheung BM and Lau GK: Pharmacokinetics of pitavastatin in subjects with child-pugh A and B cirrhosis. Br J Clin Pharmacol. 59:291–297. 2005. View Article : Google Scholar : PubMed/NCBI
7	Labi V, Grespi F, Baumgartner F and Villunger A: Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: A breakthrough in anticancer therapy? Cell Death Differ. 15:977–987. 2008. View Article : Google Scholar : PubMed/NCBI
8	Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB and Richardson A: The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res. 13:7191–7198. 2007. View Article : Google Scholar : PubMed/NCBI
9	Stamelos VA, Robinson E, Redman CW and Richardson A: Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells. Gynecol Oncol. 128:377–382. 2013. View Article : Google Scholar : PubMed/NCBI
10	Abed MN, Abdullah MI and Richardson A: Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells. J Ovarian Res. 9:252016. View Article : Google Scholar : PubMed/NCBI
11	Ghosh-Choudhury N, Mandal CC, Ghosh-Choudhury N and Choudhury G Ghosh: Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell Signal. 22:749–758. 2010. View Article : Google Scholar : PubMed/NCBI
12	Qi XF, Zheng L, Lee KJ, Kim DH, Kim CS, Cai DQ, Wu Z, Qin JW, Yu YH and Kim SK: HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway. Cell Death Dis. 4:e5182013. View Article : Google Scholar : PubMed/NCBI
13	Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
14	Cancer Genome Atlas Research Network, . Integrated genomic analyses of ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
15	Workman P, Clarke PA, Raynaud FI and van Montfort RL: Drugging the PI3 kinome: From chemical tools to drugs in the clinic. Cancer Res. 70:2146–2157. 2010. View Article : Google Scholar : PubMed/NCBI
16	Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar : PubMed/NCBI
17	Goldoni M and Johansson C: A mathematical approach to study combined effects of toxicants in vitro: evaluation of the bliss independence criterion and the loewe additivity model. Toxicol In Vitro. 21:759–769. 2007. View Article : Google Scholar : PubMed/NCBI
18	Richardson A, Malik RK, Hildebrand JD and Parsons JT: Inhibition of cell spreading by expression of the C-terminal domain of focal adhesion kinase (FAK) is rescued by coexpression of Src or catalytically inactive FAK: A role for paxillin tyrosine phosphorylation. Mol Cell Biol. 17:6906–6914. 1997. View Article : Google Scholar : PubMed/NCBI
19	Kato S, Smalley S, Sadarangani A, Chen-Lin K, Oliva B, Brañes J, Carvajal J, Gejman R, Owen GI and Cuello M: Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med. 14:1180–1193. 2010.PubMed/NCBI
20	Taylor-Harding B, Orsulic S, Karlan BY and Li AJ: Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells. Gynecol Oncol. 119:549–556. 2010. View Article : Google Scholar : PubMed/NCBI
21	Vidot S, Witham J, Agarwal R, Greenhough S, Bamrah HS, Tigyi GJ, Kaye SB and Richardson A: Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell Signal. 22:926–935. 2010. View Article : Google Scholar : PubMed/NCBI
22	Miraglia E, Högberg J and Stenius U: Statins exhibit anticancer effects through modifications of the pAkt signaling pathway. Int J Oncol. 40:867–875. 2012.PubMed/NCBI
23	Hanrahan AJ, Schultz N, Westfal ML, Sakr RA, Giri DD, Scarperi S, Janakiraman M, Olvera N, Stevens EV, She QB, et al: Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov. 2:56–67. 2012. View Article : Google Scholar : PubMed/NCBI
24	Huang J, Zhang L, Greshock J, Colligon TA, Wang Y, Ward R, Katsaros D, Lassus H, Butzow R, Godwin AK, et al: Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer. 50:606–618. 2011. View Article : Google Scholar : PubMed/NCBI
25	Robinson E, Fisher N, Stamelos V, Redman C and Richardson A: New strategies for the treatment of ovarian cancer. Biochem Soc Trans. 42:125–129. 2014. View Article : Google Scholar : PubMed/NCBI
26	Liu H, Yang J, Yuan Y, Xia Z, Chen M, Xie L, Ma X, Wang J, Ouyang S, Wu Q, et al: Regulation of Mcl-1 by constitutive activation of NF-κB contributes to cell viability in human esophageal squamous cell carcinoma cells. BMC Cancer. 14:982014. View Article : Google Scholar : PubMed/NCBI
27	Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA and Letai A: Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 9:351–365. 2006. View Article : Google Scholar : PubMed/NCBI
28	Stamelos VA, Redman CW and Richardson A: Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine. J Mol Signal. 7:122012. View Article : Google Scholar : PubMed/NCBI
29	Stamelos VA, Fisher N, Bamrah H, Voisey C, Price JC, Farrell WE, Redman CW and Richardson A: The BH3 mimetic obatoclax accumulates in lysosomes and causes their alkalinization. PLoS One. 11:e01506962016. View Article : Google Scholar : PubMed/NCBI
30	Stamelos V: Investigation of the BH3-mimetics navitoclax and obatoclax as potential therapeutics for ovarian cancer. PhD thesisSchool of Pharmacy Keele University Staffordshire: pp. 246ProQuest No. 1874909132. 2014
31	Del Gaizo Moore V and Letai A: BH3 profiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 332:202–205. 2013. View Article : Google Scholar : PubMed/NCBI